0
Oversigt Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen
February 12, 2019 at 7:07 AM CET
Media Release:
Copenhagen, Denmark, February 12, 2019
DARZALEX split dosing regimen approved by U.S. FDA
Provides healthcare professionals with option to split first DARZALEX infusion over two consecutive days
Approval supported by data from EQUULEUS (MMY1001) clinical tria
Læs mere:
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-us-fda-approval-darzalexr-daratumumab-split